Jonathan Hasian Haposan

Jonathan Hasian Haposan

Auto-generated profile, based on publicly available information

Jonathan Hasian Haposan

Universitas Gadjah Mada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in Vaccine
Verified
Journal Article
Open access
JTJarir At Thobari
Jarir At Thobari
WDWahyu Damayanti
Wahyu Damayanti
JHJonathan Hasian Haposan
Jonathan Hasian Haposan
HNHera Nirwati
Hera Nirwati
KIKristy Iskandar
Kristy Iskandar
YSYati Soenarto
Yati Soenarto
Despite safe and effective WHO prequalified rotavirus vaccines, at least 84 million children remain unvaccinated. A birth dose schedule of the RV3-BB vaccine was reported to be highly efficacious against severe rotavirus disease in Indonesian infants and is under further development at PT Bio Farma, Indonesia. The aim is to develop a rotavirus vaccine starting from birth that could improve the implementation, safety, and effectiveness of vaccines. A multi-site phase I study of a human neonatal RV3 rotavirus vaccine (Bio Farma) in adults, children, neonates in Indonesia from April 2018 to March 2019. The adult and child cohorts were open-labeled single-dose, while the neonatal cohort was randomized, double-blind, and placebo-controlled three-doses at the age of 0-5 days, 8-10 weeks, and 12-14 weeks. The primary objective was to assess the safety of vaccines with the immunogenicity and vaccine virus fecal shedding as the secondary endpoints in neonates. Twenty-five adults, 25 children, and 50 neonates were recruited, and all but one in the neonatal cohort completed all study procedures. Three serious adverse events were reported (1 adult & 2 neonates), but none were assessed related to investigational product (IP). The neonatal vaccine group had a significantly higher positive immune response (cumulative seroconverted SNA and IgA) 28 days after three doses than those in the placebo group (72% vs. 16.7%, respectively). The GMT of serum IgA in the vaccine group was significantly higher at post IP dose 1 (p < 0.05) and post IP dose 3 (p < 0.001) compared to the placebo group. The trial results show that the RV3 rotavirus vaccine (Bio Farma) is well tolerated in all participant cohorts (adults, children, and neonates). Three doses of this vaccine administered in a neonatal schedule were immunogenic. These promising results support further clinical development of the RV3 rotavirus vaccine (Bio Farma).

1 July 2025 in Journal of Primary Care & Community Health
Verified
Journal Article
Open access
LLLutfian Lutfian
Lutfian Lutfian
Izdihar Javier WardikaIzdihar Javier Wardika
Izdihar Javier Wardika
MMMuhammad Amirul Mukminin
Muhammad Amirul Mukminin
IHIbnu Syarifudin Hidayat
Ibnu Syarifudin Hidayat
RWRiki Wartakusumah
Riki Wartakusumah
JHJonathan Hasian Haposan
Jonathan Hasian Haposan
Background: Type 2 Diabetes Mellitus (T2DM) presents a significant public health challenge, particularly in developing countries, where healthcare resources are limited. Community-Based Interventions (CBIs) have been explored as a strategy to improve glycemic control, yet evidence regarding their efficacy in reducing HbA1c levels in these settings remains limited. Aim: This study aimed to evaluate the efficacy of community-based interventions in improving HbA1c levels among patients with T2DM in developing countries. Methods: A systematic review and meta-analysis were performed following PRISMA guidelines. A comprehensive literature search was conducted in PubMed, Scopus, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, Ovid-Medline, and Cumulative Index to Nursing and Allied Health Literature (CINAHL) databases for full-text randomized controlled trials (RCTs) published between 2015 and 2024. Studies conducted in developing countries focusing on community-based interventions targeting HbA1c outcomes were included. Quality appraisal was conducted using the Joanna Briggs Institute (JBI) critical appraisal tools. Statistical analysis employed a random-effects model to calculate the pooled mean difference (MD) with 95% confidence intervals (CI). Heterogeneity was assessed using the I 2 statistic. Potential publication bias was assessed using Egger’s test, the Trim-and-Fill method, and a funnel plot. Results: Twenty RCTs involving 4914 participants across developing countries were included. CBIs significantly reduced HbA1c levels compared to usual care, with a pooled MD of −0.54 (95% CI = −0.71, −0.36; P < .00001; I 2 = 92%). Subgroup analysis showed that education-focused interventions (MD = −0.67; 95% CI = −1.02, −0.31) and physical activity-focused interventions (MD = −0.67; 95% CI = −1.14, −0.20) were the most effective. Analysis by income level revealed no significant differences in efficacy between lower-middle-income and upper-middle-income countries ( P = .29). The greatest HbA1c reduction was observed during the 0- to 3-month measurement period (MD = −0.56; 95% CI = −0.90, −0.23). Conclusion: CBIs are an effective strategy for reducing HbA1c levels among patients with T2DM in developing countries, with significant benefits across diverse economic contexts and intervention models. These findings highlight the adaptability and scalability of CBIs, underscoring their potential to enhance diabetes management in resource-limited settings.

1 July 2025 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
Sidik MaulanaSidik Maulana
Sidik Maulana
LLLutfian Lutfian
Lutfian Lutfian
Izdihar Javier WardikaIzdihar Javier Wardika
Izdihar Javier Wardika
RFRahmat Fadhli
Rahmat Fadhli
DADesfara Anggreani
Desfara Anggreani
HHHartiah Haroen
Hartiah Haroen
Introduction: Current knowledge regarding tuberculosis (TB) medication adherence largely stems from scientific publications. However, to date, the volume and characteristics of studies specifically focused on TB medication adherence in Southeast Asia have not yet been systematically assessed. This study aims to conduct a comprehensive bibliometric analysis of research on medication adherence in TB treatment within this region. Methods: A bibliometric analysis was conducted using the Scopus database to identify research articles related to medication adherence in TB treatment in Southeast Asia, published in English between 2015 and 2024. The analysis included the number of publication trends, country of origin, citation metrics, co-authorship networks, keyword co-occurrence, and the most frequently cited documents. Results: A total of 146 journal articles were retrieved. Indonesia emerged as the most prolific contributor and demonstrated strong international collaboration. Keyword co-occurrence analysis revealed four major research themes: (1) clinical and demographic characteristics, (2) pharmacological management and disease burden, (3) socio-behavioral factors related to adherence, and (4) digital health-based treatment evaluation. Burst analysis of reference and keyword highlighted emerging research trends, particularly in “primary-community based care” and “digital health interventions”, indicating potential trajectories for future research in TB medication adherence. Conclusion: This study provided an overview of the evolving research landscape on TB medication adherence in Southeast Asia. These findings highlight the growing emphasis on primary-community based care and digital health interventions, pointing toward shaping future research and practice.

28 June 2021 in Jurnal Pengabdian kepada Masyarakat (Indonesian Journal of Community Engagement)
Verified
Journal Article
Open access
PDF file
JTJarir At Thobari
Jarir At Thobari
WDWahyu Damayanti
Wahyu Damayanti
AMAsal Wahyuni Erlin Mulyadi
Asal Wahyuni Erlin Mulyadi
JHJonathan Hasian Haposan
Jonathan Hasian Haposan
ASAnnisa Setiyaningrum
Annisa Setiyaningrum
YSYati Soenaro
Yati Soenaro
Introduction: Diarrhea is still a leading cause of death in the world in children, especially in children under 5 years. Diarrhea is a contagious disease with relatively high morbidity and mortality rates. Rotavirus is a cause of diarrhea in children and is a very important public health problem in both developed and developing countries. Parents' knowledge is one of the causes of diarrhea due to parents' ignorance of the causes of diarrhea, how diarrhea is transmitted and how to prevent diarrhea.Methods: This explanatory mixed qantitative-qualitative method with a quasi experimental design study to determine the effect of interactive discussion on changes in knowledge, attitudes, and perceptions towards the prevention and management of childhood diarrhea among mothers and children living in the area of The Ash-Shiddiqiyah Orphanage located in Central Sremo, Hargowilis, Kokap, Kulon Progo Regency, Yogyakarta.Results: The activities were conducted on November 29th, 2020 with 67 participants consisting of 54 children and 13 mothers from the area. The questionnaire results showed that the posttest scores in all sections (knowledge, attitudes, and perceptions) were significantly higher compared to the the pretest scores. There were increment of 1.33 points in knowledge (p<0.001), 0.5 points in attitudes (p<0.001), 0.4 points in perception (p<0.05), and 0.76 points in overall scores (p<0.001). Interviewees agreed that the intervention has been properly conducted with clear delivery, easy to understand for both adults and children, and ability to two-way communication. Technology utilization might help the understanding of the audience. Besides, a small group discussion in the session may benefit the participants to ask more confidently compared to asking in the middle of large group due to shame.Conclusion: Interactive discussion could be used to improve knowledge, atittude and perception towards childhood diarrhea. The delivery of interactive discussion using simple language for targetted population, adoption of small group discussion and technology utilization might help the effectiveness of the intervention. Further study is needed to identify effective ways to promote the childhood diarrhea management and prevention in community.

1 December 2020 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
MAM.F. Adda’i
M.F. Adda’i
JHJ.H. Haposan
J.H. Haposan
HKH.T. Kusumawardani
H.T. Kusumawardani
AHA.K.T. Haruni
A.K.T. Haruni

26 October 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JTJarir At Thobari
Jarir At Thobari
ILIda Safitri Laksono
Ida Safitri Laksono
JHJonathan Hasian Haposan
Jonathan Hasian Haposan
HIHardini Tri Indarti
Hardini Tri Indarti
AMAsal Wahyuni Erlin Mulyadi
Asal Wahyuni Erlin Mulyadi
JBJulie Bines
Julie Bines
Background: Typhoid fever, caused by the bacterium Salmonella enterica serovar Typhi ( S. Typhi), remains a major global threat despite substantial declines over the past three decades. In 2021, an estimated 7.1 million (5.6 to 9.2 million) cases occurred worldwide. Following the WHO’s recommendation, ten countries (excluding Indonesia) have introduced the typhoid conjugate vaccine (TCV). To inform decision-making for the potential introduction of TCV into Indonesia’s National Immunisation Program, we estimated the direct and indirect costs of typhoid fever in Indonesia. Methods: We conducted a multisite, incidence-based cost-of-illness study using a patient-level bottom-up costing approach in 23 hospitals and primary health centres (PHCs) across six provinces. Children (6 months to 17 years) and adults (≥18 years) hospitalised with ICD-10 A01 typhoid fever hospitalised with at least one positive typhoid serodiagnostic result during 2019-2023 (retrospective) and 2022-2023 (prospective), without other major infectious or chronic comorbidities, were identified from facility records. Direct medical costs were obtained retrospectively from hospital/PHC bills and clinical records, while direct non-medical and indirect (productivity loss) costs were collected prospectively through interviewer-administered household questionnaires. Sensitivity analyses re-estimated costs after excluding component-wise outliers and imputing missing income values using the provincial minimum wage. Results: We collected 2,069 records (1,538 retrospective [891 children; 647 adults] and 531 prospective [329 children; 202 adults]) across six provinces. The weighted mean direct medical costs were US$177.0 ± 101.9 for children and US$199.8 ± 119.8 for adults, while the corresponding direct non-medical costs were US$43.7 ± 16.3 and US$39.0 ± 10.9, respectively. Indirect costs were US$23.9. ± 5.6 (children) and US$17.9 ± 5.5 (adults). Private hospitals had the highest total direct medical cost (US$254.4), while PHCs had the lowest (US$47.8). Costs varied substantially by provinces (BPJS tariff regions). Conclusion: Hospitalised typhoid fever imposes a substantial economic burden in Indonesia. These setting- and region-specific cost estimates can inform cost projections and cost-effectiveness analyses for the introduction of the typhoid conjugate vaccine in Indonesia.